Combination immune-checkpoint inhibition with chemotherapy is a clinical standard yet concurrent administration may limit the full benefit of immunotherapy by blunting the proliferation and differentiation of CD8 T cells. Identifying patients where sequential chemo-immunotherapy or immunotherapy alone is feasible should be a priority to optimize long-term outcomes.

中文翻译：

---

揭示序贯化学免疫疗法的治疗益处

免疫检查点抑制与化疗联合治疗是临床标准，但同时给药可能会削弱 CD8 T 细胞的增殖和分化，从而限制免疫治疗的全部益处。确定序贯化疗免疫治疗或单独免疫治疗可行的患者应该是优化长期结果的优先事项。